Mineralys Closes Tanabe Termination, Owns Lorundrostat IP Outright but Keeps $265M Milestones
MLYS is trading near its 52-week low of $20.12 (5.6% above the low).
Summary
Mineralys terminated its Tanabe license and took direct ownership of the lorundrostat patents, while keeping up to $265.0 million of milestone payments and a Japan-only right of first negotiation with Tanabe. No material termination penalty was incurred.
Key Events · M&A and Partnerships · MLYS
-
Tanabe License Terminated, IP Assigned
On October 27, 2026, Mineralys terminated the July 9, 2020 License Agreement and received assignment of the lorundrostat patents and know-how from Tanabe.
-
$265M Milestones Survive Restructuring
Under the new Payment Obligation Agreement, the company still owes up to $255.0 million in commercial milestones plus up to $10.0 million for a second indication.
-
Change-of-Control Trigger Removed
The prior $100.0 million acceleration on a change of control tied to U.S. lorundrostat rights no longer sits inside the license; the milestone obligations continue under the new agreement.
-
No Early Termination Penalty
The company stated it did not incur any material early termination penalties in connection with terminating the License Agreement.
Analysis · MLYS · Life Sciences
Mineralys now owns the lorundrostat patents and know-how outright rather than licensing them, which removes the change-of-control trigger that would have made $100.0 million of milestones immediately due if the company were acquired. That matters because a December 2026 FDA decision on lorundrostat is the central event for this stock, and a clean, unencumbered asset is easier to partner or sell. The trade-off: the $255.0 million of commercial milestones plus up to $10.0 million for a second indication survive under the new Payment Obligation Agreement, so the cash cost did not disappear — it was restructured, and Tanabe keeps a Japan-only right of first negotiation until those milestones are paid. No material early termination penalty was incurred.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, MLYS was trading at $21.24 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.9B. The 52-week trading range was $20.12 to $47.65. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.